MedPath

Transplantation of autologous and G-CSF mobilized mononuclear cells in patients with critical limb ischemia (CLI)

Not Applicable
Conditions
CLI (Atherosclerotic PAD/Buerger disease )
Registration Number
JPRN-UMIN000005227
Lead Sponsor
Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
5
Inclusion Criteria

Not provided

Exclusion Criteria

1) CLI within category 6 on the Rutherford's scale 2) Less than 3 months since success of bypass surgery, transluminal angioplasty and sympathectomy for the limb expected to be transplanted 3) Left ventricular ejection fraction < 25% 4) Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis 5) Patients with malignant tumor 6) Patients with diabetic proliferating retinopathy (new Fukuda classification ii to BV) 7) Less than 3 months since last episode of unstable angina and myocardial/cerebral infarction 8) Patients with hematological disease (leukemia, myeloproliferative disease, myelodysplastic syndromes or sickle cell anemia) 9) Patients with collagen diseases 10) Patients with cirrhosis of the liver 11) Patients currently suffering from or having a history of interstitial pneumonitis 12) Patients with cerebral aneurysm judged to require treatment by a neurosurgeon 13) Leukocytes less than 4,000/micro L or exceeding 15,000/micro LL 14) Platelets less than 100,000/micro L 15) Hemoglobin less than 8 g/dL 16) AST(GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L 17) Patients for whom abdominal CT reveals splenomegaly 18) Patients with rest pain, ulcer or necrosis for reasons other than CLI (such as lumber spinal canal stenosis, arthropathy or vasculitis), 19) Patients who require major amputation regardless of whether revascularization is successful or not, because of exposure of the bone or tendon due to osteomyelitis, osteonecrosis, ulcer and soft tissue necrosis, or sepsis 20) Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period 21) Patients enrolled in any other clinical trial 22) Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath